Tecovirimat monohydrate

Overview

Tecovirimat (ST-246) monohydrate is the monohydrate form of Tecovirimat ( HY-14805 ). Tecovirimat monohydrate is an orally bioavailable and selective compound against orthopoxviruses [including vaccinia, monkeypox, camelpox, cowpox, ectromelia (mousepox), smallpox and variola viruses]. Tecovirimat monohydrate is evaluated against vaccinia, cowpox virus, ectromelia virus with EC 50 values of 0.01 μM, 0.48 μM and 0.05 μM, respectively. Tecovirimat monohydrate targets the orthopoxvirus protein VP37 which is necessary for membrane envelopment of intracellular mature virus particles to form enveloped virus. Tecovirimat monohydrate exerts antiviral activity on the target of the cowpox virus V061 gene , which is homologous to vaccinia virus F13L , encoding a major envelope protein (p37) required for production of extracellular virus. Tecovirimat monohydrate could be used in the study for orthopoxvirus-induced diseases.

Application

Products | Products > Disease Areas > Infection | Products > Disease Areas > Viral Infection | Products > Disease Areas > Orthopoxvirus Infection | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Infection | Products > Signaling Pathways > Orthopoxvirus | Products > Signaling Pathways > Arenavirus

Product Information

• Catalog No.: HY-14805A
• CAS No.: 1162664-19-8
• Molecular Formula: C19H17F3N2O4
• Molecular Weight: 394.34
• Purity: 97.35%
• Storage: 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Solubility: ≥ 2.5 mg/mL (6.34 mM); Clear solution
• Availability: In-stock

Source

Original product source